Skip to main content
YIFAN PHARMACEUTICAL CO.,LTD logo

YIFAN PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 002019 ISIN · CNE000001K65 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,499 across all filing types
Latest filing 2021-11-30 Transaction in Own Shar…
Country CN China
Listing Shenzhen Stock Exchange 002019

About YIFAN PHARMACEUTICAL CO.,LTD

https://www.yifanyy.com

Yifan Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and commercialization of innovative biologics, specialty small molecules, and traditional Chinese medicine. The company maintains a diverse product portfolio, notably featuring Ryzneuta (efbemalenograstim alfa), a long-acting recombinant human granulocyte colony-stimulating factor used to treat chemotherapy-induced neutropenia. It is also recognized as a major global supplier of Vitamin B5 (D-calcium pantothenate). Operating with a global perspective, the firm manages integrated R&D and production platforms that adhere to international quality standards. Its core activities span drug discovery, clinical development, and large-scale manufacturing, with a strategic emphasis on therapeutic areas such as oncology, hematology, and dermatology.

Recent filings

Filing Released Lang Actions
关于回购公司股份实施进展暨回购完成的公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement from a company about the progress and completion of its share repurchase program. It details the number of shares repurchased, the price range, the total amount spent, compliance with regulatory rules, and the intended use of the repurchased shares for employee incentive plans. It does not contain financial statements or detailed financial analysis but rather reports on the share buyback activity and its compliance. This fits the definition of a Transaction in Own Shares (POS) filing, which covers company announcements about buying back or selling its own shares.
2021-11-30 Chinese
关于全资子公司再次通过高新技术企业认定的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement from a company about its wholly-owned subsidiary receiving a High-Tech Enterprise Certificate, which allows for preferential tax treatment. It states the certificate details, the impact on tax rates, and confirms no effect on the current year's performance but potential positive impact on future years. There are no financial statements, no detailed financial data, no earnings results, no management discussion, no regulatory certifications, or meeting materials. The document is brief (652 characters) and serves as a regulatory announcement about a tax status update. This fits best under Regulatory Filings (RNS) as it is a general regulatory announcement that does not fit other specific categories.
2021-11-29 Chinese
关于对全资子公司提供担保的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the progress of providing a guarantee by the company for its wholly-owned subsidiary. It details the guarantee contract, financial data of the subsidiary, board approvals, and compliance with regulatory requirements. The document is relatively short (2542 characters) and focuses on a specific financing-related guarantee update rather than a full financial report or audit. It does not contain comprehensive financial statements or detailed financial analysis. Therefore, it fits best under the category of Capital/Financing Update (CAP), which covers updates on company financing activities or capital structure changes such as guarantees.
2021-11-26 Chinese
关于全资子公司参与全国药品集中采购拟中选的公告
Regulatory Filings Classification · 95% confidence The document is an announcement by a company about its wholly-owned subsidiary's participation and tentative selection in a national drug procurement program. It details product information, potential impact on the company, and risk warnings. The document is short (1264 characters) and does not contain financial statements or detailed financial data. It is an update on a business event related to product procurement and market impact, not a financial report or regulatory filing. It does not fit categories like Annual Report, Interim Report, Earnings Release, or Audit Report. It is also not a management or board change announcement. The document is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement about a business development that does not fit other specific categories.
2021-11-26 Chinese
关于继续使用部分闲置募集资金暂时补充流动资金的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from 亿帆医药股份有限公司 regarding the continued use of idle raised funds to temporarily supplement working capital. It details the approval by the board of directors, the amount and source of the funds, compliance with regulatory requirements, and opinions from the supervisory board, independent directors, and the sponsoring institution. The document does not contain financial statements or detailed financial performance data but rather focuses on the use of capital raised from a previous private placement and the related approvals and compliance. The length is 4206 characters, which is relatively short and consistent with an announcement rather than a full report. This fits the category of Capital/Financing Update (CAP), as it concerns the use and management of raised capital funds.
2021-11-18 Chinese
申万宏源证券承销保荐有限责任公司关于亿帆医药股份有限公司继续使用部分闲置募集资金暂时补充流动资金的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed verification opinion from a securities underwriting and sponsorship company regarding the continued use of idle raised funds by a pharmaceutical company for temporary working capital supplementation. It references regulatory guidelines, specific fundraising events (2017 non-public stock issuance), and internal approvals by the company's board and supervisory committee. The document includes detailed financial figures about the raised funds, their usage, and compliance with regulatory requirements. It is not a full annual or interim financial report, nor an earnings release or call transcript. It is a formal verification or audit opinion related to the use of raised capital funds, which aligns with the category of Audit Report / Information (AR). The document length is under 5,000 characters but contains substantive content and detailed financial data, not merely an announcement or certification letter, so it is not Regulatory Filings (RNS) or Report Publication Announcement (RPA). Therefore, the best classification is AR with high confidence. FY 2021
2021-11-18 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.